ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2008 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--July 31, 2008--ImmunoGen, Inc. (Nasdaq: IMGN) will host a conference call at 4:30 pm EDT on Thursday, August 7, 2008 to discuss the Company's financial results for the three-month period and fiscal year ended June 30, 2008. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through August 14, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies, and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis and Biogen Idec also are testing TAP compounds in the clinic, and a naked antibody is in clinical trials through the Company's collaboration with sanofi-aventis.
CONTACT: ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
SOURCE: ImmunoGen, Inc.
